• Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228).
  

PubMed=1568228
Metcalf R.A., Welsh J.A., Bennett W.P., Seddon M.B., Lehman T.A., Pelin-Enlund K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B.I., Harris C.C.
p53 and Kirsten-ras mutations in human mesothelioma cell lines.
Cancer Res. 52:2610-2615(1992)

CLPUB00243
Kahlos K.
The expression and possible role of manganese superoxide dismutase in malignant pleural mesothelioma.
Thesis PhD (1999), University of Oulu, Finland

PubMed=11283936; DOI=10.1002/1097-0142(20010401)91:7<1349::AID-CNCR1138>3.0.CO;2-D
Kahlos K., Soini Y., Sormunen R., Kaarteenaho-Wiik R., Paakko P., Linnainmaa K., Kinnula V.L.
Expression and prognostic significance of catalase in malignant mesothelioma.
Cancer 91:1349-1357(2001)

PubMed=12707267; DOI=10.1074/jbc.M302161200
Vivo C., Liu W.-H., Broaddus V.C.
c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells.
J. Biol. Chem. 278:25461-25467(2003)

PubMed=23422483
Chaouche-Mazouni S., Copin M.-C., Lassalle P., Lebaili N., Cortot A., Scherpereel A.
M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.
In Vivo 27:227-232(2013)